Recruiting PHASE3 INTERVENTIONAL 2-arm NCT07226700

Suzetrigine in Total Hip Arthroplasty

A Randomized, Placebo-controlled, Double-blind Trial of Suzetrigine in Total Hip Arthroplasty

Sponsor: Hospital for Special Surgery, New York

Conditions JOURNAVX Multimodal Analgesia Nav 1.8 Opioid Cessation Opioid Consumption, Postoperative Pain Pain Management Randomized Controlled Study Randomized Controlled Trial Randomized Controlled Trials Suzetrigine Total Hip Arthroplasty (THA) Total Hip Arthroplasty \(THA\) Total Hip Replacement Total Hip Replacement Arthroplasty Total Hip Replacement Surgery Total Hip Replacements

Interventions Placebo Suzetrigine

Updated 2 times since 2025 Last updated: Jan 27, 2026 Started: Nov 3, 2025 Primary completion: Nov 1, 2027 Completion: Nov 1, 2028

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE3 trial investigates JOURNAVX and Multimodal Analgesia and is currently actively recruiting participants. Hospital for Special Surgery, New York leads this study, which shows 2 recorded versions since 2025 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

2 versions recorded

Feb 2026 — Present [monthly]

Recruiting PHASE3

Status: Not Yet Recruiting → Recruiting
Dec 2025 — Feb 2026 [monthly]

Not Yet Recruiting PHASE3

First recorded

Nov 2025

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Hospital for Special Surgery, New York

Data source: Hospital for Special Surgery, New York

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• New York, United States